BMRN
BioMarin Pharmaceutical Inc price
0% Past Week
Market Cap
16.65B
Day’s Range
52W Range
Volume (3M)
1.26M
Price-Earnings Ratio
171.27
Revenue
2.19B
BioMarin Pharmaceutical Inc Latest News
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by UncertaintyBenzinga3 days ago
D.B. Root & Company LLC Buys 290 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)The AM Reporter3 days ago
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting | BMRN Stock NewsStock Titan10 days agoAbout BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc is a leading global biotechnology company headquartered in San Rafael, California, with locations in the United States, South America, Asia, and Europe. Established in 1997, BioMarin is engaged in the development and commercialisation of therapies for rare genetic diseases in children and adults, with its main focus on enzyme replacement therapies and various types of gene therapy.
The firm has successfully brought to market various treatments for rare genetic diseases such as achondroplasia, phenylketonuria, morquio A syndrome, and CLN2 disease, with more products at various research stages in the firm’s pipeline. BioMarin owns and operates its own manufacturing facilities, allowing for a high degree of quality control and efficiency in its manufacturing process. These facilities include three current Good Manufacturing Practices (cGMP) plants in Novato, California, and Shanbally, Ireland.
The firm has around 3,000 employees worldwide, and Forbes named BioMarin one of America’s Best Midsize Employers in 2019. The firm owns various subsidiary companies, including Prosensa, BioMarin Europe Ltd., Zacharon Pharmaceuticals Inc., Glyko Inc., Huxley Pharmaceuticals Inc., and LEAD Therapeutics Inc. The company is listed on the NASDAQ, where it trades under the ticker BMRN.
Add BMRN stock to your eToro watchlist today to get real-time updates on Biomarin share price movements.
Show MoreJean-Jacques Bienaimé, MBA
CEO
3K
Employees
1997
Founded
San Rafael, California, US
HQ
Upcoming Events
25
OCT
REPORTS
BioMarin Pharmaceutical Inc Q3 2023 earnings report is expected to be released after market open
Consensus
Moderate Buy
Price Target
122.00
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
61
Very High
Industry
Avg. 45
58
Environment
70
Social
53
Governance
Business Involvement Flags
GMO
Companies engaged in plant and animal breeding, genetics and genomics, including
animal and plant DNA testing services.
People Also Bought
BIIB Biogen Inc -0.32% 
BEZ.L Beazley PLC -0.18% 
INSP Inspire Medical Systems Inc. -0.97% 
RPRX Royalty Pharma PLC 1.34% 
SEAT Vivid Seats Inc (Class A) -0.16%